logo
Aqua Illinois water problems expand to University Park, Governors State University sends alert

Aqua Illinois water problems expand to University Park, Governors State University sends alert

CBS News4 hours ago

Issues with unsafe drinking water from Aqua Illinois in the south suburbs have now expanded to University Park, Illinois, as Governors State University sent out an alert to its community Monday morning.
The university said a drinking water alert has been issued for the University Park area due to elevated levels of nitrates in the Kankakee River, which may be harmful to infants under 6 months old. The alert also warns not to boil the water, as boiling water can actually worsen the elevated nitrate levels.
Water with elevated nitrate levels is also unsafe for pregnant women and people with certain health conditions.
Friday, Aqua Illinois notified families in Will and Kankakee counties about the unsafe tap water in those areas too.
"Aqua Illinois has never before experienced a nitrate exceedance at our Kankakee Water Treatment Plant," the company said Friday. "It is our assessment that spring fertilization and recent rains caused elevated nitrate levels in the river. Because of the unprecedented nature of this incident, we will be providing bottled water to certain high-risk customers in the impacted service area."
The utility provider said bottled water should be used to prepare formula for infants. Generally, infants under 6 months old should not drink water outside of what is found in breastmilk or used for formula, according to the American Academy of Pediatrics.
Aqua Illinois said it is distributing bottled water to people affected, though they have not announced distribution points in University Park yet. For more information, contact Aqua Illinois at 877-987-2782.
Please note: The above video is from a previous report

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ASCO 2025: Key Updates in Early Breast Cancer Care
ASCO 2025: Key Updates in Early Breast Cancer Care

Medscape

time13 minutes ago

  • Medscape

ASCO 2025: Key Updates in Early Breast Cancer Care

Mariana Chavez MacGregor, MD, MSc, comments on how the ASCO 2025 meeting delivered a wealth of impactful data, particularly in the early-stage breast cancer setting. Trials like neoCARHP and CompassHER2 raised important questions about de-escalating therapy for HER2-positive patients, challenging the role of carboplatin and demonstrating strong pathologic complete response rates with shorter regimens. Long-term data from SOFT and TEXT reinforced the survival benefits of ovarian suppression plus an aromatase inhibitor in high-risk premenopausal patients, and the OASIS 4 study showed promise with elinzanetant in managing vasomotor symptoms. Across subtypes, including triple-negative disease, and with the growing role of AI and circulating tumor DNA, the meeting emphasized more personalized, less toxic approaches to care.

ASCO 2025: Key Highlights in Advanced Lung Cancer
ASCO 2025: Key Highlights in Advanced Lung Cancer

Medscape

time13 minutes ago

  • Medscape

ASCO 2025: Key Highlights in Advanced Lung Cancer

Just returned from ASCO 2025, Isabel Preeshagul, DO, comments on intriguing data that were presented, including results from REZILIENT1, which showed a 35% response rate for zipalertinib in patients with epidermal growth factor receptor exon 20-altered stage IV non-small cell lung cancer (NSCLC), even those previously treated with targeted therapies, with manageable toxicity. An unexpected finding from another study in the advanced NSCLC space suggested that administering immunochemotherapy before 3:00 PM was associated with better outcomes, possibly due to circadian influences on immune response. In extensive-stage small cell lung cancer, tarlatamab demonstrated superiority over chemotherapy in the DeLLphi-304 trial, with favorable patient-reported outcomes including improved cough and exertional shortness of breath. Finally, Dr Preeshagul notes how the IMforte study reported promising results for maintenance atezolizumab plus lurbinectedin, with improved progression-free survival and overall survival, making it a potential option pending further risk-benefit discussion.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store